Atherosclerosis: Diet and Drugs

1. Front Matter

   Pages I-XII

   PDF

2. Background

   1. The Pathogenesis of Atherosclerosis

      • P. Cullen, J. Rauterberg, S. Lorkowski

      Pages 3-70

   2. Risk Factors for Atherosclerotic Vascular Disease

      • A. von Eckardstein

      Pages 71-105

   3. Metabolic Syndrome: Therapeutic Considerations

      • S.M. Grundy

      Pages 107-133

3. The Impact of Diet

   1. Physical Activity, Obesity and Cardiovascular Diseases

      • T.A. Lakka, C. Bouchard

      Pages 137-163

   2. Fatty Acids and Atherosclerotic Risk

      • M.A. Thijssen, R.P. Mensink

      Pages 165-194

   3. Dietary Cholesterol, Atherosclerosis and Coronary Heart Disease

      • M. Kratz

      Pages 195-213

   4. Plant Sterols and Stanols

      • M.J. Tikkanen

      Pages 215-230

   5. Carbohydrates and Dietary Fiber

      • P.M. Suter

      Pages 231-261

   6. Dietary Antioxidants and Paraoxonases Against LDL Oxidation and Atherosclerosis Development

      • M. Aviram, M. Kaplan, M. Rosenblat, B. Fuhrman

      Pages 263-300

   7. Soy, Isoflavones and Atherosclerosis

      • R. St. Clair, M. Anthony

      Pages 301-323

   8. Homocysteine and B Vitamins

      • S. Cook, O.M. Hess

      Pages 325-338

   9. Alcohol

      • H.F.J. Hendriks, A. van Tol

      Pages 339-361

4. Evidence-Based Anti-Atherosclerotic Drug Therapy

   1. Lipid and Non-lipid Effects of Statins

      • R. Paoletti, C. Bolego, A. Cignarella

      Pages 365-388

   2. Fibrates

      • R. Robillard, C. Fontaine, G. Chinetti, J.-C. Fruchart, B. Staels

      Pages 389-406

   3. ACE Inhibitors and Angiotensin II Receptor Antagonists

      • A. Dendorfer, P. Dominiak, H. Schunkert

      Pages 407-442

   4. Inhibition of Platelet Activation and Aggregation

      • I. Ahrens, C. Bode, K. Peter

      Pages 443-462

5. Targets of Future Anti-Atherosclerotic Drug Therapy

   1. The ABC of Hepatic and Intestinal Cholesterol Transport

      • T. Plösch, A. Kosters, A.K. Groen, F. Kuipers

      Pages 465-482

   2. Inhibition of the Synthesis of Apolipoprotein B-Containing Lipoproteins

      • J. Greeve

      Pages 483-517

   3. Therapy of Hyper-Lp(a)

      • K.M. Kostner, G.M. Kostner

      Pages 519-536

Cardiovascular diseases continue to be the leading cause of death in the - jority of industrialized countries. The most frequent underlying pathology, namely atherosclerosis, and its clinical sequelae, namely coronary heart d- ease, cerebrovascular disease and peripheral artery disease, remain common although for a long time we have been made aware of avoidable or mo- ?able etiological factors such as smoking, fat-rich diet or lack of exercise, and although these adverse lifestyle factors have been extensively addressed by population-wide primary prevention programs. Cardiovascular morbidity and mortality also remain high despite successful anti-hypertensive and lipid lowering drug therapies which help to reduce cardiovascular morbidity and mortality by about 30% in both secondary and tertiary prevention settings. This can partly be explained by the increasing life expectancy and growing p- portionofelderly people,especiallyinEuropeandNorthAmerica. Inaddition, the World Health Organization makes the alarming prediction that probably in response to the spreading of western dietary behavior and lack of exercise resulting in an increasing prevalence of diabetes, dyslipidemia and hypert- sion, cardiovascular diseases rather than infectious diseases will become the most frequent cause of death worldwide. This volume of the Handbook of Experimental Pharmacology entitled “Atherosclerosis” is divided into four parts and intends to give an overview on the pathogenesis of atherosclerosis, established treatment and prevention regimen, and of perspectives for the development of new treatment modalities.

• Angiotensin II
• atherosclerosis
• cardiovascular
• gene therapy
• heart disease
• prevention
• risk factors
• vascular biology
• metabolic disease

• Institute of Clinical Chemistry, University Hospital of Zurich, Zürich, Switzerland

  Arnold Eckardstein

Policies and ethics